{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Seizure%2C+Partial+Onset",
    "query": {
      "condition": "Seizure, Partial Onset"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 103,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Seizure%2C+Partial+Onset&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T02:50:17.639Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01243177",
      "title": "Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy",
        "Monotherapy"
      ],
      "interventions": [
        {
          "name": "Lacosamide",
          "type": "DRUG"
        },
        {
          "name": "Carbamazepine-Controlled Release",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB BIOSCIENCES GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 888,
      "start_date": "2011-04",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2021-02-02",
      "last_synced_at": "2026-05-22T02:50:17.639Z",
      "location_count": 15,
      "location_summary": "Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 12 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01243177"
    },
    {
      "nct_id": "NCT07233239",
      "title": "A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Focal Seizures"
      ],
      "interventions": [
        {
          "name": "CBD-OS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 100,
      "start_date": "2025-11-26",
      "completion_date": "2027-11-29",
      "has_results": false,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-05-22T02:50:17.639Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • La Jolla, California • New Haven, Connecticut + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07233239"
    },
    {
      "nct_id": "NCT01494584",
      "title": "Study in Pediatric Subjects With Epilepsy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "ezogabine/retigabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 5,
      "start_date": "2012-07-25",
      "completion_date": "2013-04-29",
      "has_results": true,
      "last_update_posted_date": "2020-11-30",
      "last_synced_at": "2026-05-22T02:50:17.639Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Wellington, Florida • Memphis, Tennessee + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Wellington",
          "state": "Florida"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01494584"
    },
    {
      "nct_id": "NCT00655551",
      "title": "Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Partial Epilepsies",
        "Partial Onset Seizures"
      ],
      "interventions": [
        {
          "name": "lacosamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB BIOSCIENCES, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "16 Years to 60 Years"
      },
      "enrollment_count": 100,
      "start_date": "2008-04",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2018-07-17",
      "last_synced_at": "2026-05-22T02:50:17.639Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Baltimore, Maryland • Chesterfield, Missouri + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Chesterfield",
          "state": "Missouri"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00655551"
    },
    {
      "nct_id": "NCT04839601",
      "title": "RNS System RESPONSE Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Epilepsy",
        "Partial Seizure",
        "Neurostimulator; Complications",
        "Drug Resistant Epilepsy",
        "Focal Epilepsy"
      ],
      "interventions": [
        {
          "name": "RNS System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "NeuroPace",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 9,
      "start_date": "2021-10-27",
      "completion_date": "2025-05-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-22",
      "last_synced_at": "2026-05-22T02:50:17.639Z",
      "location_count": 2,
      "location_summary": "Grand Rapids, Michigan • Hawthorne, New York",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Hawthorne",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04839601"
    },
    {
      "nct_id": "NCT02477839",
      "title": "Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy With Partial-onset Seizures"
      ],
      "interventions": [
        {
          "name": "Lacosamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "UCB BIOSCIENCES, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "47 Months",
        "sex": "ALL",
        "summary": "1 Month to 47 Months"
      },
      "enrollment_count": 255,
      "start_date": "2015-06-05",
      "completion_date": "2020-05-28",
      "has_results": true,
      "last_update_posted_date": "2021-07-01",
      "last_synced_at": "2026-05-22T02:50:17.639Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Tampa, Florida • Henderson, Nevada + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Henderson",
          "state": "Nevada"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02477839"
    },
    {
      "nct_id": "NCT01262677",
      "title": "Once-A-Day Pregabalin For Partial Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Partial Seizures",
        "Epilepsies, Partial"
      ],
      "interventions": [
        {
          "name": "pregabalin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 325,
      "start_date": "2011-02-17",
      "completion_date": "2012-08-01",
      "has_results": true,
      "last_update_posted_date": "2021-01-25",
      "last_synced_at": "2026-05-22T02:50:17.639Z",
      "location_count": 26,
      "location_summary": "Northport, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 15 more",
      "locations": [
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01262677"
    },
    {
      "nct_id": "NCT02849626",
      "title": "Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Partial-Onset or Primary Generalized Tonic-Clonic Seizures"
      ],
      "interventions": [
        {
          "name": "Perampanel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "4 Years to 12 Years"
      },
      "enrollment_count": 180,
      "start_date": "2016-11-16",
      "completion_date": "2021-12-06",
      "has_results": true,
      "last_update_posted_date": "2022-10-28",
      "last_synced_at": "2026-05-22T02:50:17.639Z",
      "location_count": 29,
      "location_summary": "Little Rock, Arkansas • Palo Alto, California • Aurora, Colorado + 25 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        },
        {
          "city": "Loxahatchee Groves",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02849626"
    },
    {
      "nct_id": "NCT05481905",
      "title": "ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Epilepsy"
      ],
      "interventions": [
        {
          "name": "ENX-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Engrail Therapeutics INC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-09",
      "completion_date": "2024-12",
      "has_results": false,
      "last_update_posted_date": "2023-07-06",
      "last_synced_at": "2026-05-22T02:50:17.639Z",
      "location_count": 38,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Downey, California + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05481905"
    },
    {
      "nct_id": "NCT05716100",
      "title": "A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Focal Onset Seizures"
      ],
      "interventions": [
        {
          "name": "XEN1101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xenon Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 360,
      "start_date": "2023-05-09",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-05-22T02:50:17.639Z",
      "location_count": 19,
      "location_summary": "Little Rock, Arkansas • Downey, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05716100"
    }
  ]
}